Company news
Exagen Inc. (NASDAQ:XGN) news
Every Exagen Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Exagen Inc. Reports Second Quarter 2026 Financial Results
August 4, 2026
Exagen Inc. to Participate in Upcoming Investor Conference
July 28, 2026
Exagen to Announce Second Quarter Financial Results on August 4, 2026
July 21, 2026
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus
June 1, 2026
Exagen Inc. Reports First Quarter 2026 Results
May 11, 2026
Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026
April 27, 2026
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results
March 10, 2026
Exagen Inc. to Participate in Upcoming Investor Conferences
March 3, 2026
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
February 24, 2026
Exagen Inc. Announces Select Preliminary 2025 Financial Results
January 11, 2026
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
November 11, 2025
Exagen Inc. Reports Strong Q3 2025 Results
November 4, 2025
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
October 23, 2025
Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025
October 21, 2025
Exagen Inc. to Participate in Third Quarter Investor Conferences
August 6, 2025
Exagen Inc. Reports Strong Q2 2025 Results
July 29, 2025
Exagen Inc. Appoints Chas McKhann to Board of Directors
July 17, 2025
Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025
July 15, 2025
Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics
June 23, 2025
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
May 9, 2025
Exagen Inc. Prices Public Offering of Common Stock
May 8, 2025
Exagen Inc. Announces Proposed Public Offering of Common Stock
May 7, 2025
Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume
May 5, 2025
Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors
April 28, 2025
Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025
April 21, 2025
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
March 11, 2025
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
February 25, 2025
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024...
January 12, 2025
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
December 12, 2024
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
November 14, 2024
Exagen Inc. Reports Third Quarter 2024 Results
November 12, 2024
Exagen to Announce Third Quarter 2024 Results on November 12, 2024
October 29, 2024
Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence
October 21, 2024
Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference
September 4, 2024
Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance
August 5, 2024
Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 2, 2024
Exagen Appoints Jeffrey G. Black as New Chief Financial Officer
August 1, 2024
Exagen to Announce Second Quarter 2024 Results on August 5, 2024
July 22, 2024
Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year
May 13, 2024
Exagen Announces Campaign for Lupus Awareness Month
May 6, 2024
Exagen to Announce First Quarter 2024 Results on May 13, 2024
April 30, 2024
Exagen Inc. Announces Changes to the Board of Directors
April 26, 2024
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results
March 18, 2024
Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
March 8, 2024
Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024
March 7, 2024
Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
January 30, 2024
Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance
January 7, 2024
Exagen Inc. Reports Strong Third Quarter 2023 Results
November 13, 2023
Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers
November 9, 2023
Exagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
November 2, 2023